ZIOPHARM, Inc. Announces ZIO-101 Anti-Cancer Activity At American Association for Cancer Research
WASHINGTON--(BUSINESS WIRE)--April 5, 2006--ZIOPHARM Oncology, Inc. (OTC BB: ZIOP - News) announced today the results of a preclinical study that show ZIO-101, a new organic arsenic drug, kills myeloma cells. The data, presented during the Annual Meeting of the American Association of Cancer Research, suggest ZIO-101 might be active in cancers where arsenic trioxide (ATO) is ineffective or too toxic.